Chronic Selective Endothelin A Receptor Antagonism Reduces Serum Uric Acid in Hypertensive Chronic Kidney Disease

Dhaun, Neeraj; Johnston, Neil R.; Goddard, Jane; Webb, David J.

doi:10.1161/hypertensionaha.111.175646

Cited by 12 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to the active comparator, lisinopril at a usual maintenance dose of 20 mg daily, the difference in treatment effect with aprocitenan was approximately −5.0/−3.0 mmHg 27 . Interestingly, aprocitentan also reduced serum uric acid, an effect seen with other ERAs, 28,29 and which, if maintained longer‐term, would be expected to translate to improved CVD outcomes 27 . Phase II studies of aprocitentan in TRH have demonstrated encouraging results, and a phase III trial, the PRECISION study, is underway 30…”

Section: Using Existing Antihypertensive Agents More Effectivelymentioning

confidence: 99%

Hypertension: Current trends and future perspectives

Hunter

Chapman

Dhaun

2021

Brit J Clinical Pharma

Self Cite

View full text Add to dashboard Cite

Hypertension is a significant and increasing global health issue. It is a leading cause of cardiovascular disease and premature death worldwide due to its effects on end organs, and through its associations with chronic kidney disease, diabetes mellitus and obesity. Despite current management strategies, many patients do not achieve adequate blood pressure (BP) control. Hypertension-related cardiovascular mortality rates are rising in tandem with the increasing global prevalence of chronic kidney disease, diabetes mellitus and obesity. Improving BP control must therefore be urgently prioritised. Strategies include utilising existing antihypertensive agents more effectively, and using treatments developed for co-existing conditions (such as sodium-glucose cotransporter 2 inhibitors for diabetes mellitus) that offer additional BP-lowering and cardiovascular benefits. Additionally, novel therapeutic agents that target alternative prohypertensive pathways and that offer broader cardiovascular protection are under development, including dual angiotensin receptor-neprilysin inhibitors. Nonpharmacological strategies such as immunotherapy are also being explored. Finally, advancing knowledge of the human genome and molecular modification technology may usher in an exciting new era of personalised medicine, with the potential to revolutionise the management of hypertension.

show abstract

Section: Using Existing Antihypertensive Agents More Effectivelymentioning

confidence: 99%

Hypertension: Current trends and future perspectives

Hunter

Chapman

Dhaun

2021

Brit J Clinical Pharma

Self Cite

View full text Add to dashboard Cite

show abstract

“…In fact, ET-1 directly stimulates inflammation both in the vasculature and the kidney, and this occurs in the absence of hypertension. 7, 17, 34 Recently, it was shown that an ET A receptor specific antagonist reduces blood pressure and proteinuria in patients with CKD. 34 These reductions were in addition to the normal treatments already being administered, including angiotensin receptor blockers and converting enzyme inhibitors.…”

Section: Endothelin In Chronic Kidney Diseasementioning

confidence: 99%

“…7, 17, 34 Recently, it was shown that an ET A receptor specific antagonist reduces blood pressure and proteinuria in patients with CKD. 34 These reductions were in addition to the normal treatments already being administered, including angiotensin receptor blockers and converting enzyme inhibitors. Therefore, while the initial insult in the development of chronic kidney disease may be multi-factorial and complex, ET-1 appears to play an important role in the development and progression of the disease.…”

Section: Endothelin In Chronic Kidney Diseasementioning

confidence: 99%

Endothelin, Kidney Disease, and Hypertension

Speed

Pollock

2013

Hypertension

View full text Add to dashboard Cite

“…Recent studies showed that selective ETA receptor antagonism in hypertensive patients with chronic kidney disease results in reduction of blood pressure, proteinuria, arterial stiffness, and serum uric acid [34][35][36].…”

Section: Eras In Chronic Kidney Diseasementioning

confidence: 99%

Endothelin Receptor Antagonists (ERA) in Hypertension and Chronic Kidney Disease: a Rose with Many Thorns

Doumas¹,

Athyros²,

Katsiki³

et al. 2013

TOHYPERJ

View full text Add to dashboard Cite

Abstract:The discovery of endothelin created a lot of enthusiasm and paved new therapeutic avenues for the treatment of arterial hypertension. Endothelin plays a significant role in blood pressure regulation through pronounced vasoconstriction and modulation of sodium and water reabsorption in the kidneys. Endothelin receptor antagonists have been tested in many clinical trials in patients with arterial hypertension, heart failure, pulmonary arterial hypertension, systemic sclerosis, chronic kidney disease, and diabetic nephropathy. However, the results were usually disappointing, except in pulmonary hypertension and scleroderma digital ulcers. The future of ERAs for the treatment of arterial hypertension and chronic kidney disease does not seem bright, and only the combination with other classes of antihypertensive drugs might offer a way out.

show abstract

Chronic Selective Endothelin A Receptor Antagonism Reduces Serum Uric Acid in Hypertensive Chronic Kidney Disease

Cited by 12 publications

References 13 publications

Hypertension: Current trends and future perspectives

Hypertension: Current trends and future perspectives

Endothelin, Kidney Disease, and Hypertension

Endothelin Receptor Antagonists (ERA) in Hypertension and Chronic Kidney Disease: a Rose with Many Thorns

Contact Info

Product

Resources

About